Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma

References

• Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66:791–820.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L, et al Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248–255.
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209–220.
   PubMed Web of Science ®Google Scholar
• Wang F, Xu RH, Luo HY, et al Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008;8:115.
   PubMed Web of Science ®Google Scholar
• Liang XF, Chen YS, Wang XJ, et al [A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old]. Chin J Epidemiol 2005;26:655–658. [in Chinese].
   Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68–69.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13–23.
   PubMed Web of Science ®Google Scholar
• Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085–1089.
   PubMed Web of Science ®Google Scholar
• Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155:1053–1056.
   PubMed Web of Science ®Google Scholar
• Sera T, Hiasa Y, Michitaka K, et al Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721–724.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kawamura T, Saitoh S, et al Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627–629.
   PubMed Web of Science ®Google Scholar
• Westhoff TH, Jochimsen F, Schmittel A, et al Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, et al Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268–276.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605–611.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–539.
   PubMed Web of Science ®Google Scholar
• Li YH, He YF, Jiang WQ, et al Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320–1325.
   PubMed Web of Science ®Google Scholar
• Hsu C, Hsiung CA, Su IJ, et al A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008;47:844–853.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–242.
   PubMed Web of Science ®Google Scholar
• Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179–1197.
   PubMed Web of Science ®Google Scholar
• Shen L, Li JQ, Zeng MD, Lu LG, Fan ST, Bao H. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol 2006;12:1292–1295.
   PubMed Web of Science ®Google Scholar
• Kami M, Hamaki T, Murashige N, et al Safety of rituximab in lymphoma patients with hepatitis B or hepatitis-C virus infection. Hematol J 2003;4:159–162.
   PubMedGoogle Scholar
• Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001;8:311–321.
   PubMed Web of Science ®Google Scholar
• Zell JA, Yoon EJ, Ignatius Ou SH, Hoefs JC, Chang JC. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs 2005;16:83–85.
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998–1005.
   PubMed Web of Science ®Google Scholar